Effect of high-dose clopidogrel according to CYP2C19∗2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis

Thrombosis Research

Volumn 135, Issue 3, 2015, Pages 449-458

  Zhang, Lanning ^a   Yang, Jie ^a   Zhu, Xiaoquan ^a   Wang, Xuyun ^a   Peng, Li ^a   Li, Xiaoqi ^a   Cheng, Peng ^a   Yin, Tong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cardiovascular events; Clopidogrel; CYP2C19 2; High dose; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; NITRIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ARTICLE; CARDIOVASCULAR DISEASE; COCHRANE LIBRARY; DRUG MEGADOSE; EMBASE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; STENT THROMBOSIS; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; ADVERSE EFFECTS; ALLELE; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; DRUG EFFECTS; GENETICS; PROCEDURES; STENT; THROMBOCYTE; THROMBOSIS;

ALLELES; BLOOD PLATELETS; CYTOCHROME P-450 CYP2C19; GENOTYPE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; STENTS; THROMBOSIS; TICLOPIDINE;

EID: 84925819104     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.12.007     Document Type: Article

References (52)

1. J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, and D.E. Casey Jr. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 127 2013 e663 e828
2. N. Mallouk, C. Labruyere, J.L. Reny, C. Chapelle, M. Piot, and P. Fontana Prevalence of poor biological response to clopidogrel: a systematic review Thromb Haemost 107 2012 494 506
3. S.A. Scott, K. Sangkuhl, C.M. Stein, J.S. Hulot, J.L. Mega, and D.M. Roden Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update Clin Pharmacol Ther 94 2013 317 323
4. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
5. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
6. T. Bauer, H.J. Bouman, J.W. van Werkum, N.F. Ford, J.M. ten Berg, and D. Taubert Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis BMJ 343 2011 d4588
7. M.V. Holmes, P. Perel, T. Shah, A.D. Hingorani, and J.P. Casas CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis JAMA 306 2011 2704 2714
8. M. Zabalza, I. Subirana, J. Sala, C. Lluis-Ganella, G. Lucas, and M. Tomas Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel Heart 98 2012 100 108
9. Food and Drug Administration (clopidogrel) in patients who are poor metabolizers of the drug [safety announcement] Available at www.fda.gov March 12 2010 [Accessed April 26, 2010]
10. Y.H. Jeong, K.A. Abadilla, U.S. Tantry, Y. Park, J.S. Koh, and C.H. Kwak Influence of CYP2C19∗2 and∗3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2 N3 study J Thromb Haemost 11 2013 1194 1197
11. J.L. Mega, W. Hochholzer, A.L. Frelinger III, M.J. Kluk, D.J. Angiolillo, and D.J. Kereiakes Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
12. J.P. Collet, J.S. Hulot, G. Anzaha, A. Pena, T. Chastre, and C. Caron High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2) JACC Cardiovasc Interv 4 2011 392 402
13. L. Bonello, L. Camoin-Jau, J. Mancini, J. Bessereau, C. Grosdidier, and M.C. Alessi Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade Thromb Res 130 2012 70 74
14. Y.H. Jeong, I.S. Kim, Y. Park, M.K. Kang, J.S. Koh, and S.J. Hwang Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study JACC Cardiovasc Interv 3 2010 731 741
15. S.J. Hwang, Y.H. Jeong, I.S. Kim, K.S. Park, M.K. Kang, and J.S. Koh Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention Circ Cardiovasc Interv 3 2010 450 459
16. D. Alexopoulos, I. Xanthopoulou, P. Davlouros, T.E. Plakomyti, A. Panagiotou, and E. Mavronasiou Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel Am Heart J 162 2011 733 739
17. L. Bonello, S. Armero, O. Ait Mokhtar, J. Mancini, P. Aldebert, and N. Saut Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19∗2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
18. G. Campo, G. Parrinello, P. Ferraresi, B. Lunghi, M. Tebaldi, and M. Miccoli Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
19. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
20. D. Sibbing, W. Koch, S. Massberg, R.A. Byrne, J. Mehilli, and S. Schulz No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 32 2011 1605 1613
21. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, and K. Dorrler Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
22. K.A. Tiroch, D. Sibbing, W. Koch, T. Roosen-Runge, J. Mehilli, and A. Schomig Protective effect of the CYP2C19∗17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J 160 2010 506 512
23. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
24. M.J. Price, S.S. Murray, D.J. Angiolillo, E. Lillie, E.N. Smith, and R.L. Tisch Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study J Am Coll Cardiol 59 2012 1928 1937
25. T. Cuisset, J. Quilici, W. Cohen, L. Fourcade, N. Saut, and M. Pankert Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome Am J Cardiol 108 2011 760 765
26. I.S. Kim, Y.H. Jeong, Y. Park, K.S. Park, S.E. Yun, and J.R. Park Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype J Am Coll Cardiol Intv 4 2011 381 391
27. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
28. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
29. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
30. L. Zhang, Y. Chen, Y. Jin, F. Qu, J. Li, and C. Ma Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients Thromb Res 132 2013 81 87
31. A.D. Furlan, V. Pennick, C. Bombardier, and M. van Tulder updated method guidelines for systematic reviews in the Cochrane Back Review Group Spine (Phila Pa 1976) 34 2009 1929 1941
32. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
33. C. Combescure, P. Fontana, N. Mallouk, P. Berdague, C. Labruyere, and I. Barazer Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 8 2010 923 933
34. J.L. Reny, C. Combescure, Y. Daali, and P. Fontana Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis J Thromb Haemost 10 2012 1242 1251
35. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
36. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
37. S. Duval, and R. Tweedie Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
38. L. Bonello, A. De Labriolle, M. Scheinowitz, G. Lemesle, P. Roy, and D.H. Steinberg Emergence of the concept of platelet reactivity monitoring of response to thienopyridines Heart 95 2009 1214 1219
39. S.S. Brar, J. ten Berg, R. Marcucci, M.J. Price, M. Valgimigli, and H.S. Kim Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
40. G.W. Stone, B. Witzenbichler, G. Weisz, M.J. Rinaldi, F.J. Neumann, and D.C. Metzger Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
41. D. Trenk, G.W. Stone, M. Gawaz, A. Kastrati, D.J. Angiolillo, and U. Muller A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
42. J.P. Collet, T. Cuisset, G. Range, G. Cayla, S. Elhadad, and C. Pouillot Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
43. G. Montalescot, G. Range, J. Silvain, J.L. Bonnet, Z. Boueri, and O. Barthelemy High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study Circulation 129 2014 2136 2143
44. J.L. Reny, P. Berdague, A. Poncet, I. Barazer, S. Nolli, and P. Fabbro-Peray Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study Circulation 125 2012 3201 3210
45. U.S. Tantry, L. Bonello, D. Aradi, M.J. Price, Y.H. Jeong, and D.J. Angiolillo Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
46. M. Chen, X.J. Liu, S.D. Yan, Y. Peng, H. Chai, and Q. Li Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease Atherosclerosis 220 2012 168 171
47. S.R. Mehta, J.F. Tanguay, J.W. Eikelboom, S.S. Jolly, C.D. Joyner, and C.B. Granger Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
48. C.S. Ernest II, D.S. Small, S. Rohatagi, D.E. Salazar, L. Wallentin, and K.J. Winters Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease J Pharmacokinet Pharmacodyn 35 2008 593 618
49. C.D. Payne, Y.G. Li, D.S. Small, C.S. Ernest II, N.A. Farid, and J.A. Jakubowski Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel J Cardiovasc Pharmacol 50 2007 555 562
50. D. Taubert, A. Kastrati, S. Harlfinger, O. Gorchakova, A. Lazar, and N. von Beckerath Pharmacokinetics of clopidogrel after administration of a high loading dose Thromb Haemost 92 2004 311 316
51. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
52. K. Umemura, T. Furuta, and K. Kondo The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects J Thromb Haemost 6 2008 1439 1441